Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease
Journal of Microbiology · 2025
DOI: 10.71150/jm.2411002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Microbiology, 2025. Verfasst von Sang Yoon Lee und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Liver and Digestive Diseases, Hallym University, Chuncheon 24253, Republic of Korea. Hauptthemen laut MEDLINE: Oligosaccharides, Synbiotics, Probiotics, Fatty Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hallym University Research Fund, National Research Foundation of Korea, Ministry of Education, Science and Technology.
Abstract (Originalsprache)
Synbiotics have become a new-age treatment tool for limiting the progression of metabolic dysfunction-associated steatotic liver disease; however, inclusive comparisons of various synbiotic treatments are still lacking. Here, we have explored and evaluated multiple synbiotic combinations incorporating three distinctive prebiotics, lactitol, lactulose and fructooligosaccharides. Of the synbiotic treatments evaluated, a combination of fructooligosaccharides and probiotics (FOS+Pro) exhibited superior protection against western diet-induced liver degeneration. This synbiotic (FOS+Pro) combination resulted in the lowest body weight gains, liver weights and liver/body weight ratios. The FOS+Pro synbiotic combination substantially alleviated liver histopathological markers and reduced serum AST and cholesterol levels. FOS+Pro ameliorated hepatic inflammation by lowering expression of proinflammatory markers including TNF-α, IL-1β, IL-6, and CCL2. FOS+Pro significantly improved steatosis by restricting the expression of lipid metabolic regulators (ACC1, FAS) and lipid transporters (CD36) in the liver. These findings are critical in suggesting that synbiotic treatments are capable of restraining western diet-induced metabolic dysfunction in the liver. Additionally, this study demonstrated that adding probiotic strains amplified the effectiveness of fructooligosaccharides but not all prebiotics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon 24253, Republic of Korea.
- Department of Nursing Daewon University College, Jecheon 27135, Republic of Korea.
- Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea.
Förderung
- Hallym University Research Fund
- National Research Foundation of Korea
- Ministry of Education, Science and Technology
- Korea Institute for Advancement of Technology
Zitieren
APA
Lee, S. Y., Lee, S. B., Kwon, G. H., Song, S. H., Park, J. H., Kim, M. J., Eom, J. A., Lee, K. J., Yoon, S. J., Park, H., Won, S. M., Jeong, J. J., Oh, K. K., Ham, Y. L., Baik, G. H., Kim, D. J., Sharma, S. P., & Suk, K. T. (2025). Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease. Journal of Microbiology. https://doi.org/10.71150/jm.2411002
Vancouver
Lee SY, Lee SB, Kwon GH, Song SH, Park JH, Kim MJ, et al. Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease. Journal of Microbiology. 2025. doi:10.71150/jm.2411002
BibTeX
@article{Lee2025,
author = {Lee, Sang Yoon and Lee, Su-Been and Kwon, Goo-Hyun and Song, Seol Hee and Park, Jeong Ha and Kim, Min Ju and Eom, Jung A and Lee, Kyeong Jin and Yoon, Sang Jun and Park, Hyunjoon and Won, Sung-Min and Jeong, Jin-Ju and Oh, Ki-Kwang and Ham, Young Lim and Baik, Gwang Ho and Kim, Dong Joon and Sharma, Satya Priya and Suk, Ki Tae},
title = {Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease},
journal = {Journal of Microbiology},
year = {2025},
doi = {10.71150/jm.2411002}
}
EUVIMED